Senores Pharma reports 62% rise in FY26 total income to Rs. 664 crore
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
The target reach is of more than 30 million young people and caregivers across 21 countries
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Highlighting KEYTRUDA & expanding cancer pipeline
Nearly one in five women worldwide are now living with obesity
We are building an AI-native operating system for pharma sales and distribution
Subscribe To Our Newsletter & Stay Updated